BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 10878366)

  • 1. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
    Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
    J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
    J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection.
    Jones DE; Buxbaum LU; Scott P
    J Immunol; 2000 Jul; 165(1):364-72. PubMed ID: 10861073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
    Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
    J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
    Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
    J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
    Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
    Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
    Belkaid Y; Von Stebut E; Mendez S; Lira R; Caler E; Bertholet S; Udey MC; Sacks D
    J Immunol; 2002 Apr; 168(8):3992-4000. PubMed ID: 11937556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
    Stobie L; Gurunathan S; Prussin C; Sacks DL; Glaichenhaus N; Wu CY; Seder RA
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8427-32. PubMed ID: 10890924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
    Sánchez-Sampedro L; Gómez CE; Mejías-Pérez E; Sorzano CO; Esteban M
    PLoS One; 2012; 7(6):e38859. PubMed ID: 22715418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.
    Colmenares M; Kima PE; Samoff E; Soong L; McMahon-Pratt D
    Infect Immun; 2003 Jun; 71(6):3172-82. PubMed ID: 12761096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of DNA vaccination against cutaneous leishmaniasis.
    Méndez S; Belkaid Y; Seder RA; Sacks D
    Vaccine; 2002 Nov; 20(31-32):3702-8. PubMed ID: 12399198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.
    Noormohammadi AH; Hochrein H; Curtis JM; Baldwin TM; Handman E
    Vaccine; 2001 Jul; 19(28-29):4043-52. PubMed ID: 11427281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.